Hong Kong international schools’ debentures and capital levies: how do they work?



A court case has thrust the financial practices of Hong Kong’s international schools into the spotlight, prompting fresh scrutiny of how they raise funds with debentures and capital levies.

On Wednesday, the US-based Lutheran Church-Missouri Synod (LCMS), which co-founded the Hong Kong International School (HKIS), said it would sue the school’s operator for allegedly breaching an operational agreement, accusing the institution of serving only the “rich and privileged few” and amassing excessive financial reserves that amounted to HK$2.8 billion (US$359 million).
The school’s operator, Hong Kong International School Association Limited (HKISAL), on Thursday rejected the allegations, claiming they were “false or irrelevant”, adding that the school was committed to supporting the international business community.

The legal challenge questioned the adequacy of safeguards for parents making significant upfront investments to buy debentures as part of the cost of their children’s education. Depending on the terms, parents can receive refunds when their children leave the school, but some are non-refundable, according to a lawyer.

“The lawsuit implicitly fuels calls for regulatory evolution, as the LCMS’s proposed alternative school without debentures spotlights how these fees can clash with accessibility goals,” said Tom Chan Pak-lam, a lawyer and veteran stockbroker.

“In my view, a review is overdue to close these loopholes,” he said, adding that potential reforms could include a requirement for schools to have automatic refunds to parents in case of insolvency, reporting of reserves to the public and consumer protections like cooling-off periods.

  • Related Posts

    China’s first-tier home prices stabilise in February after 9 months of decline

    Mainland China’s first-tier new home prices were unchanged month on month in February, ending a nine-month decline, while the year-on-year decline continued to widen from tier one to tier three…

    Continue reading
    Hong Kong attracts wave of biotech IPO filings amid AI drug boom

    More than 10 loss-making biotechnology companies have filed for Hong Kong stock exchange listings this year, bringing cutting-edge drugs and artificial intelligence-powered drug discovery platforms to market, as the city’s…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *